Campath Purple Book BLA 103948

BLA number
103948
Proprietary names
Campath, Lemtrada
Proper names
alemtuzumab
Applicant
Genzyme Corporation
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Campathalemtuzumab351(a)30MG (10MG/ML)InjectionIntravenousAmpuleDiscLicensed2001-05-07
002Lemtradaalemtuzumab351(a)12MG/1.2ML (10MG/ML)InjectionIntravenousSingle-Dose VialRxLicensed2014-11-14
003Campathalemtuzumab351(a)30MG/1MLInjectionIntravenousSingle-Dose VialRxLicensed2004-10-12

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2020-08-01U001Campath351(a)DiscGenzyme Corporation
2020-08-01U002Lemtrada351(a)RxGenzyme Corporation
2020-08-01U003Campath351(a)RxGenzyme Corporation
2020-05-01R001Campath351(a)DiscGenzyme Corporation
2020-05-01R002Lemtrada351(a)RxGenzyme Corporation
2020-05-01R003Campath351(a)RxGenzyme Corporation

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Campath351(a)DiscLicensed2001-05-07
2020-05-01002Lemtrada351(a)RxLicensed2014-11-14
2020-05-01003Campath351(a)RxLicensed2004-10-12